{"id":"NCT01472185","sponsor":"Gilead Sciences","briefTitle":"Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2011-11-16","resultsPosted":"2014-10-15","lastUpdate":"2014-10-24"},"enrollment":465,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ranolazine","otherNames":["RanexaÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BEHAVIORAL","name":"Diet","otherNames":[]},{"type":"BEHAVIORAL","name":"Exercise","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Ranolazine","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \\[TZDs\\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline; Week 24","effectByArm":[{"arm":"Placebo","deltaMin":7.7,"sd":1.183},{"arm":"Ranolazine","deltaMin":7.26,"sd":1.101}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":30},"locations":{"siteCount":159,"countries":["United States","Czechia","Hungary","Poland","Romania","Russia","Serbia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["26049552"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":232},"commonTop":["Hyperglycaemia","Headache"]}}